X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (209) 209
Publication (49) 49
Book / eBook (7) 7
Conference Proceeding (3) 3
Dissertation (2) 2
Book Chapter (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (84) 84
humans (76) 76
oncology (76) 76
lung cancer (45) 45
female (43) 43
article (41) 41
male (41) 41
lung neoplasms - drug therapy (37) 37
middle aged (36) 36
lung neoplasms - pathology (34) 34
aged (33) 33
respiratory system (32) 32
carcinoma, non-small-cell lung - drug therapy (31) 31
cancer (30) 30
adult (29) 29
chemotherapy (28) 28
lung cancer, non-small cell (25) 25
carcinoma, non-small-cell lung - pathology (24) 24
docetaxel (19) 19
aged, 80 and over (18) 18
care and treatment (18) 18
clinical trials (18) 18
mutation (18) 18
nivolumab (18) 18
lung neoplasms - genetics (17) 17
pembrolizumab (17) 17
cancer therapies (16) 16
cell lung-cancer (15) 15
neoplasm staging (15) 15
non-small cell lung cancer (15) 15
patients (15) 15
abridged index medicus (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
immunotherapy (14) 14
survival (14) 14
therapy (14) 14
treatment outcome (14) 14
antineoplastic agents - therapeutic use (13) 13
hematology, oncology and palliative medicine (13) 13
lung neoplasms - therapy (13) 13
nsclc (13) 13
open-label (13) 13
carcinoma, non-small-cell lung - genetics (12) 12
carcinoma, non-small-cell lung - metabolism (11) 11
disease-free survival (11) 11
gefitinib (11) 11
lung neoplasms - metabolism (11) 11
cell line, tumor (10) 10
lung neoplasms - mortality (10) 10
metastasis (10) 10
non-small cell lung carcinoma (10) 10
research (10) 10
safety (10) 10
analysis (9) 9
apoptosis (9) 9
carcinoma, non-small-cell lung - mortality (9) 9
erlotinib (9) 9
lung cancer, small cell (9) 9
lung neoplasms - immunology (9) 9
melanoma (9) 9
prognosis (9) 9
tumors (9) 9
adenocarcinoma (8) 8
bevacizumab (8) 8
carcinoma, non-small-cell lung - immunology (8) 8
clinical trials as topic (8) 8
double-blind method (8) 8
kaplan-meier estimate (8) 8
medicine, general & internal (8) 8
mutations (8) 8
paclitaxel (8) 8
pulmonary/respiratory (8) 8
receptor, epidermal growth factor - antagonists & inhibitors (8) 8
usage (8) 8
antibodies, monoclonal, humanized - therapeutic use (7) 7
biomarkers (7) 7
carcinoma, non-small-cell lung - therapy (7) 7
non-small-cell lung cancer (7) 7
quality of life (7) 7
acquired-resistance (6) 6
angiogenesis (6) 6
antibodies, monoclonal - administration & dosage (6) 6
antineoplastic agents - adverse effects (6) 6
breast-cancer (6) 6
carboplatin (6) 6
disease (6) 6
disease progression (6) 6
double-blind (6) 6
egfr (6) 6
expression (6) 6
follow-up studies (6) 6
health aspects (6) 6
ipilimumab (6) 6
metastases (6) 6
molecular targeted therapy (6) 6
multicenter (6) 6
ramucirumab (6) 6
respiratory tract diseases (6) 6
risk factors (6) 6
survival analysis (6) 6
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
UofT at Scarborough - Stacks (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
UofT at Mississauga - Stacks (2) 2
Engineering & Comp. Sci. - Stacks (1) 1
Music - Stacks (1) 1
Royal Ontario Museum - Stacks (1) 1
Thomas Fisher Rare Book - Reference (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Reference (1) 1
Victoria University E.J. Pratt - Reference (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2015, Volume 14, Issue 12 Supplement 2, pp. PL02-02 - PL02-02
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 02/2019, Volume 14, Issue 2, pp. 160 - 162
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 25, pp. 2483 - 2485
Arguably, no drug class has more radically and rapidly altered the management of non–small-cell lung cancer (NSCLC) than inhibitors of the interaction between... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | PEMBROLIZUMAB | NIVOLUMAB | DOCETAXEL | Antibodies, Monoclonal - therapeutic use | Cancer Vaccines | Humans | Immunotherapy | Neoplasms - drug therapy | Chemotherapy | Usage | Diagnosis | Lung cancer, Non-small cell | Cancer | Human subjects | Inhibitor drugs | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Cancer therapies
Journal Article
ISSN 1473-0197, 4/2017, Volume 17, Issue 8, pp. 1452 - 1461
Isolation and enumeration of circulating tumor cells (CTCs) from blood is important for determining patient prognosis and monitoring treatment. Methods based... 
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 05/2019, Volume 15, Issue 13, pp. 1481 - 1491
Aim: This pooled safety analysis was conducted to analyze incidence and management of key dacomitinib-associated adverse drug reactions (ADRs). Patients &... 
GEFITINIB | dacomitinib | PHASE-III | CONSENSUS | OPEN-LABEL | TRIAL | INDUCED-SKIN TOXICITIES | ONCOLOGY | adverse event management | DOUBLE-BLIND | AFATINIB | INHIBITORS | non-small-cell lung cancer
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | CRITERIA | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | THERAPY | NSCLC | IMMUNOTHERAPY | PD-L1 | BLOCKADE | NIVOLUMAB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Slopes | Cell survival | Medical treatment | Medical services | FDA approval | Survival | Patients | Medical centres | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers
Journal Article
JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 19, pp. 1998 - 2006
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9944, pp. 665 - 673
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article